Environmental Statement 2024

Human medicines European public assessment report (EPAR): Levetiracetam ratiopharm, levetiracetam, Date of authorisation: 26/08/2011, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Recarbrio, imipenem,cilastatin,relebactam, Date of authorisation: 13/02/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 6, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 February 2026, 15:00 (CET) to 23 February 2026, 17:00 (CET)

Human medicines European public assessment report (EPAR): Enurev Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Tovanor Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Seebri Breezhaler, glycopyrronium bromide, Date of authorisation: 28/09/2012, Revision: 14, Status: Authorised

Annex to agenda of the CHMP meeting 26-29 January 2026

Agenda of the CHMP meeting 26-29 January 2026